Myriad Genetics, Inc. (NASDAQ:MYGN) has made several developments in its EndoPredict studies.
The company now has data that shows that the EndoPredict tests are able to predict residual cancer burden in certain cancer patients. The data also shows that the tests can predict the distant recurrence in patients with invasive lobular carcinoma (ILC) compared to patients with invasive ductal carcinoma (IDC).
The data Myriad Genetics has collected from its EndoPredict tests show that EndoPredict is better at predicting breast cancer recurrence in patients than the Oncotype DX Breast Recurrence Score has been.
This is good news for the company, as the breast cancer screening market is predicted to increase in value by 2022, to almost $5.8 billion. With around 252,710 new cases of invasive breast cancer likely to occur in 2017 in the US alone, the EndoPredict tests could prove to be lifesavers.
Throughout the year, Myriad Genetics stock has been gaining well beyond what the industry itself has. With the industry rising only 1.7%, Myriad Genetics’ gain of 91.2% is an incredible feat for the company to have accomplished.
Featured Image: twitter
